Shi Y - Search Results

1

Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study.

Kostakoglu L, Mattiello F, Martelli M, Sehn LH, Belada D, Ghiggi C, Chua N, González-Barca E, Hong X, Pinto A, Shi Y, Tatsumi Y, Bolen C, Knapp A, Sellam G, Nielsen T, Sahin D, Vitolo U, Trněný M. Kostakoglu L, et al. Among authors: shi y. Haematologica. 2022 Jul 1;107(7):1633-1642. doi: 10.3324/haematol.2021.278663. Haematologica. 2022. PMID: 34407602 Free PMC article. Clinical Trial.

2

[A phase II multicenter study to investigate R-ICE as a salvage therapy for relapsed diffuse large B-cell lymphoma].

Guo Y, Chen Y, Hong X, Yu L, Ma J, Shi Y, Liu T, Jiang W, Zhu J, Jin J, Zou P, Wu D, Shen Z. Guo Y, et al. Among authors: shi y. Zhonghua Xue Ye Xue Za Zhi. 2014 Apr;35(4):314-7. doi: 10.3760/cma.j.issn.0253-2727.2014.04.014. Zhonghua Xue Ye Xue Za Zhi. 2014. PMID: 24759019 Clinical Trial. Chinese.

3

The prognostic utility and the association of serum light chains (free and total) and absolute lymphocyte count in patients with newly diagnosed diffuse large B-cell lymphoma.

Han X, Wang J, Zhang N, Yao J, Feng Y, Li D, Liu P, Yang J, Zhou S, Qin Y, Yang S, Gui L, He X, Shi Y. Han X, et al. Among authors: shi y. Leuk Res. 2014 Nov;38(11):1291-8. doi: 10.1016/j.leukres.2014.09.006. Epub 2014 Sep 22. Leuk Res. 2014. PMID: 25287608

4

Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma.

Jia B, Shi Y, Kang S, Yang S, Hu S, Li Y, Dong M, Wang W, Yang J, Zhou L, Liu P, Zhou S, Qin Y, Gui L, Zhang C, Lin H, Chen S, Wang L, He X. Jia B, et al. Among authors: shi y. Chin J Cancer Res. 2015 Oct;27(5):516-23. doi: 10.3978/j.issn.1000-9604.2015.10.04. Chin J Cancer Res. 2015. PMID: 26543339 Free PMC article.

5

[Clinicopathological characteristics and prognostic analysis of primary intestinal diffuse large B-cell lymphoma].

Huang Y, Zhou S, He X, Gui L, Yang J, Liu P, Qin Y, Zhang C, Xing P, Yang S, Wang L, Zhou L, Dong M, Sun Y, Shi Y. Huang Y, et al. Among authors: shi y. Zhonghua Yi Xue Za Zhi. 2015 Dec 19;95(48):3895-8. doi: 10.3760/cma.j.issn.0376-2491.2015.48.004. Zhonghua Yi Xue Za Zhi. 2015. PMID: 27122208 Chinese.

6

Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma.

Huang Y, Jia B, Jiang S, Zhou S, Yang J, Liu P, Gui L, He X, Qin Y, Sun Y, Shi Y. Huang Y, et al. Among authors: shi y. J Hematol Oncol. 2017 Jan 5;10(1):7. doi: 10.1186/s13045-016-0368-9. J Hematol Oncol. 2017. PMID: 28057019 Free PMC article.

7

Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study.

Hong X, Song Y, Huang H, Bai B, Zhang H, Ke X, Shi Y, Zhu J, Lu G, Liebscher S, Cai C. Hong X, et al. Among authors: shi y. Target Oncol. 2019 Apr;14(2):149-158. doi: 10.1007/s11523-019-00630-y. Target Oncol. 2019. PMID: 30904980 Free PMC article. Clinical Trial.

8

Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma.

Han Y, Yang J, Liu P, He X, Zhang C, Zhou S, Zhou L, Qin Y, Song Y, Sun Y, Shi Y. Han Y, et al. Among authors: shi y. Oncologist. 2019 Nov;24(11):e1251-e1261. doi: 10.1634/theoncologist.2018-0361. Epub 2019 Apr 5. Oncologist. 2019. PMID: 30952824 Free PMC article.

9

A prognostic nomogram constructed for relapsed or refractory diffuse large B-cell lymphoma patients.

Jiang S, Qin Y, Liu P, Yang J, Yang S, He X, Zhou S, Gui L, Zhang C, Zhou L, Sun Y, Shi Y. Jiang S, et al. Among authors: shi y. Asia Pac J Clin Oncol. 2022 Apr;18(2):e11-e16. doi: 10.1111/ajco.13222. Epub 2019 Jul 1. Asia Pac J Clin Oncol. 2022. PMID: 31264371

10

Genomic Alterations and MYD88^MUT Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib.

Jiang S, Qin Y, Gui L, Liu P, Jiang H, Liu B, Yang J, Yang S, He X, Zhou S, Du X, Yi Y, Lin J, Shi Y. Jiang S, et al. Among authors: shi y. Target Oncol. 2020 Apr;15(2):221-230. doi: 10.1007/s11523-020-00710-4. Target Oncol. 2020. PMID: 32239385

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

32,064 results

Search Page